Distinct molecular phenotype and the potential prognostic value of immune prognostic index and tumor infiltrating lymphocytes in hepatoid adenocarcinoma of stomach

Kang, Muxing; Ma, Xiaojing; Shi, Jifei; Chen, Guofeng; Jin, Xiaoli; Wang, Jun; Lin, Lele; Wu, Zixiang; Chen, Kaibo; Xu, Jinghong; Huang, Pintong; Chen, Jian

doi:10.1016/j.tranon.2022.101380

Cited by 6 publications

(4 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, in 2021, He et al analyzed 55 HAS patients and found that all these patients belonged to the CIN/GS group [ 16 ]. In 2022, Kang et al enrolled 36 HAS patients and also found that all patients belonged to CIN/GS [ 11 ]. Interestingly, they all found frequent mutations in the TP53 gene.…”

Section: Discussionmentioning

confidence: 99%

“…Subsequent survival analysis supported this hypothesis: the recurrent HAS patients who received immunotherapy with or without anti‐angiogenesis therapy achieved more favorable survival than those with traditional platinum and fluorouracil‐based chemotherapy. Kang et al enrolled 36 HAS patients in 2022 and found 9 (25%) patients with positive PD‐L1 (CPS = 1) [ 11 ]. However, no patients in their study had higher scores.…”

Section: Discussionmentioning

confidence: 99%

“…However, due to the rarity of HAS, the IHC and Epstein–Barr virus‐encoded small RNA (EBER) features of HAS have not been fully acknowledged [ 9 , 10 ]. According to previous research, HAS presents distinctive traits such as negativity for EBER, predominance of microsatellite stability (MSS), and high human epidermal growth factor receptor 2 (HER2) positive rate [ 11 , 12 ]. Nonetheless, the limited sample size affects the reliability of these conclusions.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Immunohistochemical characteristics and potential therapeutic regimens of hepatoid adenocarcinoma of the stomach: a study of 139 cases

Yang,

Wu,

Wang

et al. 2023

The Journal of Pathology CR

View full text Add to dashboard Cite

Hepatoid adenocarcinoma of stomach (HAS) is a special subtype of gastric cancer with poor prognosis. Immunohistochemical analysis could provide important clues for the treatment of HAS. A total of 159 patients were diagnosed as HAS and 139 were enrolled in this study. Statistical differences were determined using relative test methods and survival analyses were performed by the Kaplan–Meier method to find survival differences. All tumors in this study were negative for Epstein–Barr virus‐encoded small RNAs (EBERs) and almost all showed no loss of mismatch repair (MMR) proteins and were positive for alpha fetoprotein (AFP or spalt like transcription factor 4 (SALL4). About half of the tumors had a positive programmed death‐ligand 1 combined positive score (CPS) and 17.3% were positive for human epidermal growth factor receptor 2 (HER2). In addition, there was a relatively high proportion of cmet expression. We also found that HAS patients with recurrent disease treated by emerging therapy had a better survival than those treated with traditional chemotherapy (p = 0.002, median recurrence‐to‐death survival: 23 months versus 6 months); HAS patients who received anti‐HER2 therapy or harbored MMR deficiency had favorable prognosis. Overall, high proportions of MMR protein proficiency, positivity for AFP or SALL4, overexpression of HER2, CPS and cmet, as well as negative EBER findings, are distinctive characteristics of HAS patients. While negative EBER and MMR proficiency indicate molecular features of HAS, positivity for AFP or SALL4 could aid in the diagnosis of HAS. In addition, HAS patients could benefit from anti‐HER2 therapy, immunotherapy, and anti‐angiogenesis therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Immunohistochemical characteristics and potential therapeutic regimens of hepatoid adenocarcinoma of the stomach: a study of 139 cases

Yang,

Wu,

Wang

et al. 2023

The Journal of Pathology CR

View full text Add to dashboard Cite

show abstract

“…Subsequent investigations established that HAS may also manifest without elevated AFP levels ( 6 ), suggesting that elevated serum AFP serves as a hallmark of HAS but lacks absolute specificity. HAS is distinguished by its aggressive behavior and dismal prognosis in comparison to GA and HCC ( 3 , 7 – 9 ), with median survival ranging from 10 months to 18 months ( 10 , 11 ). Diagnosis often occurs at advanced stages, given the non-specific nature of clinical symptoms and imaging features.…”

Section: Introductionmentioning

confidence: 99%

Liver metastasis from hepatoid adenocarcinoma of the stomach: a case report and literature review

Zhu,

Li,

Qian

2024

Front. Oncol.

View full text Add to dashboard Cite

Hepatoid adenocarcinoma of the stomach (HAS) represents a rare malignant neoplasm sharing morphological and immunophenotypic similarities with hepatocellular carcinoma (HCC). Pathological morphology serves as the cornerstone for diagnosis, often accompanied by elevated alpha-fetoprotein (AFP) levels, nonspecific clinical symptoms, and imaging features reminiscent of gastric adenocarcinoma (GA). Liver metastases from HAS can mimic the enhancement patterns of HCC, posing challenges in differentiation from high-risk HCC cases. Conversely, HAS typically exhibits poorer prognostic outcomes compared to HCC and GA. This report presents a case of HAS with liver metastasis alongside a comprehensive literature review covering its pathology, molecular mechanisms, clinical presentations, and treatment modalities. Special focus is given to imaging characteristics and the utilization of radiomics for early-stage detection. The integration of imaging findings with laboratory results aids in HAS diagnosis, while radiomics provides novel insights for precise discrimination. In conclusion, the identification of distinct imaging markers distinguishing HAS from HCC and GA shows promise in facilitating optimal treatment strategies and improving patient outcomes.

show abstract

Volume of hepatoid component and intratumor M2 macrophages predict prognosis in patients with hepatoid adenocarcinoma of the stomach

Taniguchi,

Kiyozawa,

Kohashi

et al. 2024

Gastric Cancer

View full text Add to dashboard Cite

Background Hepatoid adenocarcinoma of the stomach (HAS), a subtype of gastric cancer (GC), includes multiple tumor components, such as enteroblastic and tubular adenocarcinoma components. However, which component mostly contributes to the aggressive behavior of HAS remains unclear. Moreover, the role of tumor-associated macrophages (TAMs) has not been explored in HAS. This study evaluated the clinical significance of the proportion of the hepatoid component within the tumor, CD163 + macrophages, and macrophage colony-stimulating factor-1 (CSF-1) in HAS. Methods In total, 56 cases of primary HAS were analyzed. In each case, hepatoid (HC), enteroblastic (EC), and tubular (TC) components were identified, and the ratio of HC to the entire tumor (hepatoid component ratio, HCR) was assessed to examine the correlation between HCR and clinicopathological features. Immunohistochemical staining for CD163 and CSF-1 was performed, and differences in immunohistochemical results among the three tumor components were analyzed. In each tumor component, the prognostic impact of CD163 and CSF-1 was examined. Results A high HCR was associated with worse overall survival (OS). CD163 + TAMs and CSF-1 immunoreactivity score in HC were significantly higher than those in the other components. High infiltration of CD163 + TAMs and a high CSF-1 immunoreactivity score in HC were associated with an aggressive course and worse OS. Multivariate analysis revealed the proportion of HC in HAS as an independent prognostic factor (HR = 3.176, p = 0.006). Conclusions The HCR and CD163 + TAMs may be useful prognostic predictors, and TAMs may be novel therapeutic targets of HAS.

show abstract

Distinct molecular phenotype and the potential prognostic value of immune prognostic index and tumor infiltrating lymphocytes in hepatoid adenocarcinoma of stomach

Cited by 6 publications

References 45 publications

Immunohistochemical characteristics and potential therapeutic regimens of hepatoid adenocarcinoma of the stomach: a study of 139 cases

Immunohistochemical characteristics and potential therapeutic regimens of hepatoid adenocarcinoma of the stomach: a study of 139 cases

Liver metastasis from hepatoid adenocarcinoma of the stomach: a case report and literature review

Volume of hepatoid component and intratumor M2 macrophages predict prognosis in patients with hepatoid adenocarcinoma of the stomach

Contact Info

Product

Resources

About